联邦遏制处方药滥用和死亡的努力使药房承受着巨大的压力，要求验证氢可酮组合产品（HCP）（例如Vicodin，lorcet和lortab）的限制性证书。使用Onekey Pharmacy Central Perscriber验证的数据，本报告详细介绍了药房客户从2016年6月至12月看到的问题的DEA数字，NPI编号，OIG排除和不活动的处方证书的数量。
The reschedule of hydrocodone combination products (HCP) in 2014 has had critical logistical implications for U.S. pharmacies. Prior to the reschedule, many pharmacies were not in the regular practice of validating prescriber DEA credentials. In fact, a 2005 CASAColumbia study found that only 70 percent of pharmacists did so on a regular basis.
但是，在当今执法的环境下，不遵守监管要求的药房面临严重后果。
Changes in HCP prescription drug policies have been unfolding since 2004, when the U.S. Drug Enforcement Agency (DEA) first attempted to tighten restrictions. In 2013, recommendations by the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee (DSaRM) led to the 2014 reschedule. Since then, federal agencies and even Congress have given serious attention to the prevention of prescription opioid abuse and deaths, the latter of which reached historic numbers (more than 165,000) in 2014 .
Despite its decision in 2008 to keep HCPs classified as schedule III drugs, the U.S. Department of Health and Human Services (HHS) has now declared opioid prescription abuse and death a public health epidemic. Pharmacies are now being called on to be partners in the effort to combat opioid prescription drug abuse and deaths. To do so, pharmacies must ensure that their validation systems and processes are equipped to access the most up-to-date prescriber DEA data available.
随着美国药房每年填写超过40亿的处方，及时，高效和准确的方式验证和验证处方者证书的能力不仅对遵从性，而且对企业至关重要。
正如该药房合规性报告所示，未遵守《联邦法规》附表II法规的药房在短短六个月内被罚款数十亿美元。此外，未能验证其他数据，包括NPI编号和OIG排除，可能会导致拒绝报销和付款提款。
Onekey Central Perscriber验证（CPV）解决方案为现代药房提供了强大，具有成本效益和简化的验证服务，以支持当前和未来的监管需求。Onekey CPV与行业中最大的医疗保健数据提供商Quintilesims的集成增加了一定程度的广度，其能力和实力无与伦必威手机APP比。